Analyzing Critical Outcome Technologies (OTCMKTS:COTQF) & MediWound (NASDAQ:MDWD)

Critical Outcome Technologies (OTCMKTS:COTQF) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends and profitability.

Profitability

This table compares Critical Outcome Technologies and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Critical Outcome Technologies	N/A	N/A	N/A
MediWound	-142.18%	-96.71%	-39.73%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Critical Outcome Technologies and MediWound, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Critical Outcome Technologies	0	0	0	0	0.00
MediWound	2	0	4	0	2.33

MediWound has a consensus target price of $32.25, indicating a potential upside of 82.67%. Given MediWound’s stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Critical Outcome Technologies.

Insider and Institutional Ownership

46.8% of MediWound shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Critical Outcome Technologies and MediWound”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Critical Outcome Technologies	N/A	N/A	N/A	N/A	N/A
MediWound	$19.86 million	9.86	-$30.22 million	($2.64)	-6.69

Critical Outcome Technologies has higher earnings, but lower revenue than MediWound.

Summary

MediWound beats Critical Outcome Technologies on 6 of the 9 factors compared between the two stocks.

About Critical Outcome Technologies

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent’s University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.